Insider · CIK 0001744627
Paul D. Burgess
Files at KLRA (Kailera Therapeutics, Inc.). First filing -, latest -.
In brief
Paul D. Burgess files SEC Form 4 as officer at KLRA (Kailera Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Paul D. Burgess has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | KLRA Kailera Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Apr 20, 2026 |
| Apr 16, 2026 | KLRA Kailera Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Apr 20, 2026 |
Questions about Paul D. Burgess
Answered from the filings on this page, as of the latest one.
Is Paul D. Burgess buying or selling?
Paul D. Burgess has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Paul D. Burgess's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Paul D. Burgess has 0.
Where does Paul D. Burgess file Form 4?
Paul D. Burgess has filed Form 4 at KLRA (Kailera Therapeutics, Inc.) as See Remarks. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.